Mounjaro(tirzepatide)
Mounjaro (tirzepatide) is a protein pharmaceutical. Tirzepatide was first approved as Mounjaro on 2022-05-13. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. It is known to target glucagon-like peptide 1 receptor and gastric inhibitory polypeptide receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Mounjaro
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tirzepatide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MOUNJARO | Eli Lilly | N-215866 RX | 2022-05-13 | 6 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mounjaro | New Drug Application | 2022-05-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TIRZEPATIDE, MOUNJARO, ELI LILLY AND CO | |||
| 2027-05-13 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | 3 | 13 | 4 | — | 26 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 5 | 1 | 9 | — | — | 15 |
| Overweight | D050177 | E66.3 | 3 | 1 | 6 | — | — | 10 | |
| Glucose metabolism disorders | D044882 | — | — | 2 | — | — | 2 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | — | — | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 2 | — | — | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 2 | — | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | 1 | — | — | 1 | |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Wolfram syndrome | D014929 | Orphanet_3463 | E13.8 | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | N18 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 | ||
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TIRZEPATIDE |
| INN | tirzepatide |
| Description | Tirzepatide, sold under the brand name Mounjaro, is an antidiabetic medication used for the treatment of type 2 diabetes. Tirzepatide is administered through subcutaneous injection (under the skin).
|
| Classification | Protein |
| Drug class | peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2023788-19-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297839 |
| ChEBI ID | — |
| PubChem CID | 156588324 |
| DrugBank | DB15171 |
| UNII ID | OYN3CCI6QE (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
Mounjaro - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 550 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mounjaro
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more